UBC

UBC is a specialized service provider in the biopharma ecosystem, focusing on the critical post-discovery stages of drug development and commercialization. The company offers integrated solutions across three core pillars: Evidence Development (real-world evidence, late-stage research), Safety & Risk Management (pharmacovigilance, REMS), and Patient Access (affordability, adherence). By leveraging expertise, real-world data, and technology, UBC aims to accelerate patient outcomes by helping biopharma clients navigate regulatory, payer, and market access complexities for specialty therapies. It operates as a private, revenue-generating services firm rather than a drug developer.

Technology-enabled services platform integrating real-world data analytics, pharmacovigilance systems, and digital patient engagement tools (including AI) to support evidence generation, risk management, and patient access solutions.

UBC competes in a fragmented market with large, full-service Contract Research Organizations (CROs like IQVIA, Parexel, PPD) that offer similar post-approval services, as well as specialized boutique firms focusing on specific areas like market access, pharmacovigilance, or patient support hubs. Its key differentiator is its integrated approach, combining evidence, safety, and access under one roof with a focus on specialty therapies and a technology-enabled, high-touch model.